Working… Menu

Zidovudine Plus Interleukin-2 and Ganciclovir in Treating Patients With AIDS-Related Primary Central Nervous System Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00006264
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : February 3, 2016
National Cancer Institute (NCI)
Information provided by:
AIDS Malignancy Consortium

Brief Summary:

RATIONALE: Antiviral drugs such as zidovudine and ganciclovir act against viruses and may be an effective treatment for HIV. Interleukin-2 may stimulate a person's white blood cells to kill lymphoma cells. Combining these treatments may be effective in treating AIDS-related primary central nervous system lymphoma.

PURPOSE: Phase II trial to study the effectiveness of combining zidovudine, ganciclovir, and interleukin-2 in treating patients who have AIDS-related primary central nervous system lymphoma.

Condition or disease Intervention/treatment Phase
Lymphoma Biological: aldesleukin Drug: ganciclovir Drug: zidovudine Phase 2

Detailed Description:


  • Determine the safety and toxicity of zidovudine, interleukin-2, and ganciclovir in patients with AIDS related primary central nervous system lymphoma.
  • Determine the response rate and overall survival of these patients treated with this regimen.

OUTLINE: This is a multicenter study.

  • Induction therapy: Patients receive zidovudine (AZT) IV and ganciclovir IV over 1 hour every 12 hours on days 1-14. Patients also receive interleukin-2 (IL-2) IV every 12 hours on days 1-14 and a combination antiretroviral therapy consisting of nucleoside reverse transcriptase inhibitors (one of which must be AZT), nonnucleoside reverse transcriptase inhibitors, and protease inhibitors. AZT and ganciclovir treatment continues for an additional 7 days if partial response is achieved.
  • Maintenance therapy: Patients receive IL-2 subcutaneously 3 times a week for 6 months. Patients also receive oral ganciclovir 3 times a day and combination antiretroviral therapy (AZT allowed, but not required). Treatment continues in the absence of disease progression or unacceptable toxicity.

Patients are followed monthly for 1 year, every 3 months for 2 years, and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 10-30 patients will be accrued for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: A Phase II Trial Of Induction Therapy With Zidovudine, Interleukin-2, And Ganciclovir In The Treatment Of HIV Positive Primary Central Nervous System Lymphoma
Study Start Date : July 2000
Actual Primary Completion Date : March 2003
Actual Study Completion Date : July 2003

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 120 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • HIV positive
  • Diagnosis of central nervous system lymphoma by one of the following means:

    • Brain biopsy
    • Thallium spectroscopy scan in conjunction with CT scan or MRI after failing to improve with at least 2 weeks of antitoxoplasmosis therapy
    • Cerebral spinal fluid positive for Epstein Barr virus in conjunction with positive thallium spectroscopy scan
    • Thallium spectroscopy scan demonstrating a thallium retention index greater than 1
  • Documented intracranial space occupying lesion
  • No systemic non-Hodgkin's lymphoma



  • 18 and over

Performance status:

  • Not specified

Life expectancy:

  • Not specified


  • Absolute granulocyte count at least 1,000/mm3
  • Platelet count at least 50,000/mm3


  • Bilirubin and SGOT no greater than 3 times upper limit of normal
  • No major hepatic dysfunction as evidenced by encephalopathy, ascites, or varices


  • Creatinine clearance at least 60 mL/min


  • No prior other malignancy within the past 5 years except carcinoma in situ of the cervix, basal cell carcinoma of the skin, or Kaposi's sarcoma not requiring systemic therapy
  • No active uncontrolled infection except HIV or Epstein Barr virus
  • No known allergy to E. coli derived products
  • Fertile patients must use effective contraception


Biologic therapy:

  • Not specified


  • Not specified

Endocrine therapy:

  • Concurrent corticosteroids allowed


  • Not specified


  • Not specified

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00006264

Layout table for location information
United States, Florida
Sylvester Cancer Center, University of Miami
Miami, Florida, United States, 33136
United States, Ohio
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
AIDS Malignancy Consortium
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: William J. Harrington, MD University of Miami Sylvester Comprehensive Cancer Center

Publications of Results:
Layout table for additonal information Identifier: NCT00006264     History of Changes
Other Study ID Numbers: AMC-019
CDR0000068204 ( Other Identifier: NCI )
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: February 3, 2016
Last Verified: February 2016
Keywords provided by AIDS Malignancy Consortium:
AIDS-related primary CNS lymphoma
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Ganciclovir triphosphate
Molecular Mechanisms of Pharmacological Action
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Anti-HIV Agents
Antineoplastic Agents
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs